Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 13/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 12/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28314178 | 0.87 | HCRTR2 (0.49) | HCRTR2HCRTR1NPC1LMNAPOLB | |
| SCHEMBL456915 | 0.86 | NAPRT (0.50) | HCRTR2HCRTR1LMNATSHR | |
| SCHEMBL30919007 | 0.86 | NAPRT (0.50) | HCRTR2HCRTR1LMNATSHR | |
| SCHEMBL19599247 | 0.85 | HCRTR2 (0.52) | HCRTR2HCRTR1NPC1LMNAPOLB | |
| SCHEMBL22235655 | 0.85 | TDP1 (0.57) | HCRTR2HCRTR1NPC1LMNAPOLB | |
| SCHEMBL4263055 | 0.84 | RAB9A (0.51) | HCRTR2HCRTR1 | |
| SCHEMBL29686939 | 0.84 | RAB9A (0.51) | HCRTR2HCRTR1 | |
| SCHEMBL19564482 | 0.84 | HCRTR2 (0.47) | HCRTR2HCRTR1NPC1LMNAPOLB | |
| SCHEMBL28816041 | 0.83 | NPC1 (0.51) | HCRTR2HCRTR1NPC1LMNAPOLB | |
| SCHEMBL12113209 | 0.80 | NPC1 (0.61) | NPC1LMNAPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017504-B2 | Piperidine isoxazole and isothiazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-10 | — | — | US | disclosed |
| US-9938276-B2 | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170327490-A1 | PIPERIDINE ISOXAZOLE AND ISOTHIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170320874-A1 | 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| WO-2016101119-A1 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016100157-A2 | 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017504-B2 | Piperidine isoxazole and isothiazole orexin receptor antagonists | HCRTR1, HCRTR2, OXTR | HCRTR2 2/4885HCRTR1 1/4885NPC1 784/4885 |
| US-20170320874-A1 | 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY5R | HCRTR2 1/4885HCRTR1 2/4885NPC1 1014/4885 |
| US-20170327490-A1 | PIPERIDINE ISOXAZOLE AND ISOTHIAZOLE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR2 1/4885HCRTR1 2/4885NPC1 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.